Palletways 51 provides distribution remedy

Send to friend

Lichfield logistics firm, Palletways 51, has won a major new contract with Kent Pharmaceuticals Ltd, Britain's largest independent pharmaceutical manufacturer, which has over 100 own label products.


 
As a member of Palletways, Europe's fastest growing and largest provider of express delivery services for palletised freight, Palletways 51 will be responsible for distributing approximately 1,200 pharmaceutical products lines for Kent Pharmaceuticals to wholesalers within the TF, DE, ST14 and Birmingham postcode areas.
 
Ashley Amos, Director at Kent Pharmaceutical Ltd said: "We chose Palletways 51 as they have an excellent reputation in the marketplace and we felt this would be a real asset for our business and enhance our service to our customers."
 
Commenting on the contract, Dez Shirley, Managing Director at Palletways 51 said: "We are proud to have been appointed by Kent Pharmaceutical Ltd and look forward to working and growing our business with them. We specialise in providing the total logistics solution tailored to the needs of each customer, enabling businesses to make cost efficiencies within their supply chain."  
 
Palletways 51 is one of 100 plus Palletways member companies - all independent transport providers with local knowledge and expertise - which make up the UK distribution network and provide a range of express delivery services for small consignments of goods across the country as well as to mainland Europe. Utilising each other's' resources all the member companies deliver goods to market faster and more cost effectively than traditional haulage methods.
 
Palletways, which was set up in 1994, has 280 depots across the UK and mainland Europe and handles around 21,000 pallets a day through nine hub facilities across Europe. The company's distribution networks in the UK and mainland Europe are supported by an unrivalled and fully integrated IT infrastructure, which allows customers to track and trace consignments using the internet.
 

Comments (0)

Add a Comment

This thread has been closed from taking new comments.